{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:02:58Z","timestamp":1789718578744,"version":"4.0.1"},"reference-count":21,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["24JCQNJC01900"],"award-info":[{"award-number":["24JCQNJC01900"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We sought to mine the respiratory system toxicity risk signals associated with fulvestrant, with the aim to enhance clinical awareness of its respiratory toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods:<\/jats:title>\n                    <jats:p>The reporting odds ratio (ROR) and proportional reporting ratio (PRR) were employed to mine respiratory system toxicity risk signals of fulvestrant from the Tianjin Adverse Drug Reaction Monitoring Center (Tianjin Center) database and the FDA Adverse Event Reporting System (FAERS) database between January 2004 and July 2025. The mined risk signals were statistically classified and described using the Medical Dictionary for Regulatory Activities (23.1 edition).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The Tianjin Center database contained 233 adverse drug event (ADE) reports in which fulvestrant was the primary suspected drug, with 156 reports involving respiratory, thoracic, and mediastinal disorders. Cough was the most frequently reported ADE, with the strongest signals detected for throat irritation, throat tightness, and cough. The FAERS database contained 12\u2009364 ADE reports with fulvestrant as the primary suspected drug, with 818 reports involving respiratory, thoracic, and mediastinal disorders. Cough was the most frequently reported ADE, with the strongest signals detected for mediastinal fibrosis, pulmonary septal thickening, and pleural thickening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Clinical use of fulvestrant should include careful monitoring for respiratory adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00185787251415492","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T03:36:49Z","timestamp":1769657809000},"page":"448-455","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mining of Respiratory System Toxicity Risk Signals for Fulvestrant Based on the Tianjin Adverse Reaction Monitoring Center and the FDA Adverse Event Reporting System Database"],"prefix":"10.1177","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0797-4043","authenticated-orcid":false,"given":"Meisa","family":"Wang","sequence":"first","affiliation":[{"name":"Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiushuang","family":"Han","sequence":"additional","affiliation":[{"name":"Tianjin Adverse Reaction Monitoring Center for Drugs Medical Devices and Cosmetics, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Liang","sequence":"additional","affiliation":[{"name":"Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengkun","family":"Yang","sequence":"additional","affiliation":[{"name":"Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.01.006"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.99"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601629"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1473038"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2023.104039"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000485538"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1799975"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14868"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0693-x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15277"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30688-5"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13531"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S353584"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac205"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.03.004"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211012263"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62238-1"},{"key":"e_1_3_3_22_2","article-title":"Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database","author":"Yu Z","unstructured":"Yu Z, Zhu H, Liao X. Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database. Expert Opin Drug Saf. Published online 2024;12:1-7\ufeff.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787251415492","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787251415492","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787251415492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:20:17Z","timestamp":1789716017000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787251415492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/00185787251415492"],"URL":"https:\/\/doi.org\/10.1177\/00185787251415492","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}